News
Quotient Sciences Expands UK Facilities to Support the Delivery of Translational Pharmaceutics® Programs
Access Press Release
Molecule to cure. Fast.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast.
Because humanity needs solutions, fast.
Watch our video
Welcome to Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.
Our services
At Quotient Sciences, we’ve streamlined the drug development process by providing pre-formulation screening, formulation development, first-in-human trials, and clinical & commercial manufacturing services all at one CDMO, allowing us to support drug programs from candidate selection through commercial supply.
Our latest updates
Discover what’s happening at Quotient Sciences
-
Thought LeadershipMark Egerton featured in Pharma's Almanac roundtable article: What important company milestone do you anticipate reaching in 2022?In this roundtable with Pharma's Almanac, Mark Egerton, CEO of Quotient Sciences, answers the Question 'What important company milestone do you anticipate reaching in 2022?'
-
Jun 15SeminarBIO International 2022 Happy Hour Seminar: Moving Drug Substance Off the Critical PathSave your spot at our BIO happy hour seminar on June 15, "Moving Drug Substance Off the Critical Path- Streamlined Strategies to Accelerate to First-in-Human & Beyond."
-
WebinarMoving Drug Substance Off the Critical Path — Streamlined Strategies to Accelerate to First-in-Human & BeyondJoin Dr. Stephen McQuaker, Director of Drug Development Consulting, as he explores case studies to demonstrate how drug substance and drug product development plans can be accelerated through innovative science and expertise to get drug substance off the critical path.
-
Scientific PostersBPS 2022 Poster - A Phase 1 Randomized PK Study of Amilo-5MERA Phase 1, Randomized, Double-Blind, Placebo Controlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers
Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.